15.78

4.88% -0.81

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $15.78, with a volume of 1.20M. It is down -4.88% in the last 24 hours and up +0.77% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Previous Close:

$16.59

Open:

$16.49

24h Volume:

1.20M

Relative Volume:

0.84

Market Cap:

$2.03B

Revenue:

$298.30M

Net Income/Loss:

$298.21M

P/E Ratio:

7.2931

EPS:

2.1637

Net Cash Flow:

$166.93M

1W Performance:

+1.09%

1M Performance:

+0.77%

6M Performance:

+4.16%

1Y Performance:

+76.71%

1-Day Range:

$15.48

$16.54

1-Week Range:

$15.37

$16.70

52-Week Range:

$8.55

$19.25

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

128

Twitter

@AuriniaPharma

Next Earnings Date

2026-07-30

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	15.78	2.03B	298.30M	298.21M	166.93M	2.1637
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Nov-07-25	Upgrade	Jefferies	Hold → Buy
Nov-05-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-30-25	Resumed	H.C. Wainwright	Buy
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Jul 11, 2026

Liquidity Mapping Around (AUPH) Price Events - Stock Traders Daily

Jul 11, 2026

Is Aurinia Pharmaceuticals (AUPH) Using Combination LN Trials to Redefine Its LUPKYNIS Strategy? - Sahm

Jul 11, 2026

Jul 09, 2026

Price to earnings forward of Aurinia Pharmaceuticals Inc. – MUN:IKAP - TradingView

Jul 09, 2026

Jul 07, 2026

AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView

Jul 07, 2026

Jul 06, 2026

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace

Jul 06, 2026

TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo

Jul 06, 2026

Aurinia Unchanged on Unveiling Lupus Treatment - Baystreet.ca

Jul 06, 2026

Aurinia launches trial combining lupus nephritis treatments - Investing.com

Jul 06, 2026

Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy - Moomoo

Jul 06, 2026

Aurinia launches trial combining lupus nephritis treatments By Investing.com - Investing.com South Africa

Jul 06, 2026

Jul 05, 2026

Aurinia Pharmaceuticals balances autoimmune drug focus and U.S. market ambitions - ad-hoc-news.de

Jul 05, 2026

Jul 04, 2026

Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView

Jul 04, 2026

Jul 03, 2026

If EPS Growth Is Important To You, Aurinia Pharmaceuticals (NASDAQ:AUPH) Presents An Opportunity - Moomoo

Jul 01, 2026

Jun 30, 2026

Why (AUPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Jun 30, 2026

Jun 29, 2026

Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now? - Insider Monkey

Jun 29, 2026

Jun 27, 2026

IKAP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026